Indications & Uses
Platigen 10 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Cisplatin injection is given by slow intravenous infusion. It must not be given by rapid intravenous injection. Needles or intravenous sets containing aluminum parts that may come into contact with Cisplatin Injection should not be used for preparation or administration, because aluminum reacts with Cisplatin Injection, causing precipitate formation and a loss of potency. Metastatic Testicular Tumors: The usual Cisplatin Injection dose for the treatment of testicular cancer, in combination with other approved chemotherapeutic agents, is 20 mg/m2 IV daily for 5 days per cycle. Metastatic Ovarian Tumors: The usual Cisplatin Injection dose for the treatment of metastatic ovarian tumors, in combination with cyclophosphamide, is 75 to 100 mg/m2 IV per cycle once every 4 weeks (DAY 1). The dose of cyclophosphamide when used in combination with cisplatin is 600 mg/m2 IV once every four weeks (DAY 1). In combination therapy, Cisplatin Injection and cyclophosphamide are administered sequentially. As a single agent, Cisplatin Injection should be given at a dose of 100 mg/m2 IV per cycle once every four weeks. Advanced Bladder Cancer: Cisplatin Injection should be given as a single agent at a dose of 50 to 70 mg/m2 IV per cycle once every 3 to 4 weeks, depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pretreated patients, an initial dose of 50 mg/m2 per cycle repeated every 4 weeks is recommended. Non Small Cell Lung Carcinoma: Cisplatin Injection (75 mg/m2) should be given in combination with Paclitaxel (135 mg/m2) every three weeks. Or, as directed by the registered physician.
Side Effects
Severe nausea and vomiting usually start 1 to 4 hours after treatment and may last for up to a week. Cisplatin Hexal Hexal can also cause serious electrolyte disturbances, most often low magnesium, low calcium, and low potassium, linked to impaired function of the kidney tubules. Low magnesium and/or low calcium may cause symptoms such as muscle irritability or cramps, clonus, tremor, carpopedal spasm, and/or tetany.
Cautions & Contraindications
Warnings & Precautions
Renal function: Cisplatin Hexal Hexal causes kidney toxicity that builds up with repeated doses. Kidney function and serum electrolytes (magnesium, sodium, potassium and calcium) should be checked before starting Cisplatin Hexal Hexal and before each later course of treatment. To maintain urine output and reduce kidney toxicity, it is recommended that Cisplatin Hexal Hexal be given as an intravenous infusion over 6 to 8 hours. In addition, intravenous hydration with 1 to 2 litres of fluid over 8 to 12 hours before treatment, followed by adequate hydration for the next 24 hours, is recommended. Repeat courses of Cisplatin Hexal Hexal should not be given unless serum creatinine is below 1.5 mg/100 ml or BUN is below 25 mg/100 ml. Special care must be taken with patients treated with Cisplatin Hexal Hexal. Bone marrow function: Peripheral blood counts should be checked often in patients receiving Cisplatin Hexal Hexal. Although blood toxicity is usually moderate and reversible, severe thrombocytopenia and leukopenia can occur. Patients who develop thrombocytopenia need special precautions: care during invasive procedures; watching for signs of bleeding or bruising; testing urine, stools and vomit for hidden blood; and avoiding aspirin and other NSAIDs. Patients who develop leukopenia should be watched closely for signs of infection and may need antibiotics and blood product transfusions. Hearing function: Cisplatin Hexal Hexal may cause hearing damage that builds up over time, and this is more likely with high-dose regimens. A hearing test (audiometry) should be done before starting therapy, and repeated when hearing symptoms appear or clinical changes in hearing become evident. Clinically important loss of hearing may call for a dose change or stopping treatment. CNS functions: Cisplatin Hexal Hexal is known to cause nerve toxicity, so a neurological examination is advised for patients receiving treatment that contains Cisplatin Hexal Hexal. Because nerve damage may be irreversible, it is recommended that Cisplatin Hexal Hexal be stopped as soon as signs or symptoms of nerve toxicity appear. Patients receiving Cisplatin Hexal Hexal should also be watched for possible anaphylactoid reactions, and suitable equipment and medicines should be kept ready to treat them. Nausea and vomiting: Marked nausea and vomiting occur in almost all patients treated with Cisplatin Hexal Hexal and are sometimes severe enough that the dose must be reduced or treatment stopped. Cisplatin Hexal Hexal should be given only by doctors experienced in the use of chemotherapy medicines. Carcinogenicity: Secondary cancers are a possible delayed effect of many anticancer medicines, although it is unclear whether this is due to their mutagenic or immunosuppressive action. The effect of dose and length of therapy is also unknown, although the risk seems to rise with long-term use. Information is limited, but available data suggest that the risk of cancer is greatest with alkylating agents. Dental: Because Cisplatin Hexal Hexal suppresses the bone marrow, it may increase the chance of microbial infection, slow healing and gum bleeding. Wherever possible, dental work should be completed before therapy starts or postponed until blood counts have returned to normal.
Contraindications
Cisplatin should not be used in patients who already have impaired kidney function, or in those with a history of allergic reaction (hypersensitivity) to Cisplatin or other platinum-containing compounds. Cisplatin injection should also not be given to patients whose bone marrow function is suppressed (myelosuppression) or to patients with hearing impairment.